Twin Tree Management’s PTC Therapeutics PTCT Stock Holding History

Twin Tree Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-172	Closed	-$6K	–	1423
2019 Q3	$6K	Buy	+172	New	+$7.49K	﹤0.01%	1138

Other funds holding PTCT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Twin Tree Management's PTCT Position: Q4 2019 in Review

Twin Tree Management sold out of PTC Therapeutics (PTCT) in Q4 2019, closing a stake of 172 shares — an estimated $6K sold.

Twin Tree Management first reported a position in PTCT in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 206 funds tracked by Wall St. Rank hold PTCT as of Q4 2019.

Twin Tree Management reported no remaining PTC Therapeutics position as of Q4 2019 after selling out during the quarter.
Twin Tree Management sold 172 PTC Therapeutics shares in Q4 2019, an estimated $6K.
Twin Tree Management first reported a position in PTC Therapeutics in Q3 2019 and held it in 1 quarter.
Twin Tree Management's PTC Therapeutics position peaked at $6K in Q3 2019.
206 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2019.

Based on Twin Tree Management's 13F filing for Q4 2019, filed 14 Feb 2020.